Regeneron Pharmaceuticals(REGN) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $958
Moomoo News19:31 ET · Ratings
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $800
Moomoo News19:31 ET · Ratings
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
Benzinga12:00 ET
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
BenzingaMay 5 11:43 ET
Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $810
Moomoo NewsMay 1 19:31 ET · Ratings
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): 'Arguably The Most Innovative Biopharma Company I've Seen In The Last Two Decades'
Yahoo FinanceMay 1 15:40 ET

Comments

Movers and Shakers

Apr 29 20:33

Columns Today's Pre-Market Movers and Top Ratings | SPOT, NVO, SOFI, and More

Morning Movers
Gapping Up
$Hims & Hers Health (HIMS.US)$ Hims & Hers surged 34.1% and $Novo-Nordisk A/S (NVO.US)$ increased by 4%. This followed Novo Nordisk's announcement that it will broaden the availability of its weight loss drug Wegovy by offering it through telehealth providers Hims & Hers Health, Ro, and Life MD, now that the drug is no longer facing shortages in the U.S.
$SoFi Technologies (SOFI.US)$ stock rose 5.9% after...

SoFi hits record revenue: Has the turnaround arrived?

19

1

9

Teddy123

Apr 21 12:27

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

$Regeneron Pharmaceuticals (REGN.US)$
Breakthrough: FDA Clears Dupixent for 300,000 Chronic Urticaria Patients After Decade-Long Wait

韭菜变主力

Mar 19 11:50

$Regeneron Pharmaceuticals (REGN.US)$ Sold my trading position at 734. Put a limit buy order at around 600 to wait for the gap fill. The 200 week moving average is a key resistance. The company has to prove the Eylea franchise revenue will not be significantly eroded by biosimilars.

2